m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG00097)
Name
Thymoquinone
Synonyms
490-91-5; Thymoquinon; p-Cymene-2,5-dione; 2-Isopropyl-5-methyl-1,4-benzoquinone; 2,5-CYCLOHEXADIENE-1,4-DIONE, 2-METHYL-5-(1-METHYLETHYL)-; 2-Isopropyl-5-methyl-p-benzoquinone; 2-Isopropyl-5-methylbenzoquinone; Polythymoquinone; 5-Isopropyl-2-methyl-1,4-benzoquinone; 2-Isopropyl-5-methylbenzo-1,4-quinone; p-Mentha-3,6-diene-2,5-dione; NSC 2228; 2-Isopropyl-5-methylcyclohexa-2,5-diene-1,4-dione; 2-Methyl-5-isopropyl-p-benzoquinone; 2-methyl-5-propan-2-ylcyclohexa-2,5-diene-1,4-dione; NSC2228; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione; UNII-O60IE26NUF; 2-Methyl-5-isopropyl-1,4-benzoquinone; O60IE26NUF; 2,5-Cyclohexadiene-1,4-dione, 5-isopropyl-2-methyl-; NSC-2228; 5-Isopropyl-2-methyl-p-benzoquinone; MFCD00001602; 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione; p-Mentha-3,6-diene-2,5-dione (8CI); 5-Isopropyl-2-methyl-2,5-Cyclohexadiene-1,4-dione; CCRIS 7152; EINECS 207-721-1; 2-methyl-5-(methylethyl)cyclohexa-2,5-diene-1,4-dione; BRN 1939047; thymolquinone; Thymoil; AI3-17758; 4hco; p-Mentha-3,5-dione; Spectrum_001237; SpecPlus_000457; Thymoquinone, >=98%; Spectrum2_000700; Spectrum3_001345; Spectrum4_001895; Spectrum5_000550; BSPBio_003129; KBioGR_002455; KBioSS_001717; DivK1c_006553; SCHEMBL542535; SPBio_000859; CHEMBL1672002; DTXSID9060079; KBio1_001497; KBio2_001717; KBio2_004285; KBio2_006853; KBio3_002349; Thymoquinone, analytical standard; CHEBI:113532; 2-Methyl-5-iso-propylbenzoquinone; BDBM166686; ZINC164367; BCP16946; HY-D0803; WLN: L6V DVJ B1 EY1&1; 2,4-dione, 5-isopropyl-2-methyl-; ANW-41600; CCG-40027; s4761; SBB008296; AKOS003368628; MCULE-9899033250; NCGC00178250-01; NCGC00178250-05; 73940-92-8; AK101679; AS-11327; 2-Isopropyl-5-methylbenzo-1,4-quinone #; 2,4-dione, 2-methyl-5-(1-methylethyl)-; CS-0012226; FT-0612708; ST45023960; K-9199; SR-05000002192; Q7799650; SR-05000002192-2; W-202869; BRD-K97566842-001-03-5; Thymoquinone; 2-isopropyl-5-methylbenzo-1,4-quinone; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione (F8); 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione, 9CI
    Click to Show/Hide
Status
Phase 2/3
Structure
Formula
C10H12O2
InChI
1S/C10H12O2/c1-6(2)8-5-9(11)7(3)4-10(8)12/h4-6H,1-3H3
InChIKey
KEQHJBNSCLWCAE-UHFFFAOYSA-N
PubChem CID
10281
TTD Drug ID
DY4OZ6
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Apoptosis regulator BAX (BAX)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Apoptosis regulator BAX (BAX) is a therapeutic target for Thymoquinone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Thymoquinone through regulating the expression of Apoptosis regulator BAX (BAX). [1], [2]
Apoptosis regulator Bcl-2 (BCL-2)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Thymoquinone. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Thymoquinone through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). [3], [4]
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Thymoquinone. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Thymoquinone through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). [4], [5]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Thymoquinone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Thymoquinone through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). [4], [6]
RNA demethylase ALKBH5 (ALKBH5)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Thymoquinone. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Thymoquinone through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). [4], [7]
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Thymoquinone. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Thymoquinone through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). [4], [6]
YTH domain-containing family protein 2 (YTHDF2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Thymoquinone. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Thymoquinone through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). [4], [8]
Cellular tumor antigen p53 (TP53)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cellular tumor antigen p53 (TP53) is a therapeutic target for Thymoquinone. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Thymoquinone through regulating the expression of Cellular tumor antigen p53 (TP53). [9], [10]
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cellular tumor antigen p53 (TP53) is a therapeutic target for Thymoquinone. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Thymoquinone through regulating the expression of Cellular tumor antigen p53 (TP53). [10], [11]
Methyltransferase-like 16 (METTL16)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cellular tumor antigen p53 (TP53) is a therapeutic target for Thymoquinone. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of Thymoquinone through regulating the expression of Cellular tumor antigen p53 (TP53). [10], [12]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cellular tumor antigen p53 (TP53) is a therapeutic target for Thymoquinone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Thymoquinone through regulating the expression of Cellular tumor antigen p53 (TP53). [10], [13]
RNA demethylase ALKBH5 (ALKBH5)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cellular tumor antigen p53 (TP53) is a therapeutic target for Thymoquinone. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Thymoquinone through regulating the expression of Cellular tumor antigen p53 (TP53). [10], [14]
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cellular tumor antigen p53 (TP53) is a therapeutic target for Thymoquinone. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Thymoquinone through regulating the expression of Cellular tumor antigen p53 (TP53). [10], [15]
References
Ref 1 Knockdown of METTL3 inhibits enterovirus 71-induced apoptosis of mouse Schwann cell through regulation of autophagy. Pathog Dis. 2021 Jul 28;79(6):ftab036. doi: 10.1093/femspd/ftab036.
Ref 2 A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8. doi: 10.1073/pnas.0708800104. Epub 2007 Dec 11.
Ref 3 The Complex Roles and Therapeutic Implications of m(6)A Modifications in Breast Cancer. Front Cell Dev Biol. 2021 Jan 11;8:615071. doi: 10.3389/fcell.2020.615071. eCollection 2020.
Ref 4 Clinical pipeline report, company report or official report of Roche (2009).
Ref 5 Methyltransferase-like 14 silencing relieves the development of atherosclerosis via m(6)A modification of p65 mRNA. Bioengineered. 2022 May;13(5):11832-11843. doi: 10.1080/21655979.2022.2031409.
Ref 6 Mettl3 inhibits the apoptosis and autophagy of chondrocytes in inflammation through mediating Bcl2 stability via Ythdf1-mediated m(6)A modification. Bone. 2022 Jan;154:116182. doi: 10.1016/j.bone.2021.116182. Epub 2021 Sep 13.
Ref 7 ALKBH5 inhibited autophagy of epithelial ovarian cancer through miR-7 and BCL-2. J Exp Clin Cancer Res. 2019 Apr 15;38(1):163. doi: 10.1186/s13046-019-1159-2.
Ref 8 A dynamic N(6)-methyladenosine methylome regulates intrinsic and acquired resistance to tyrosine kinase inhibitors. Cell Res. 2018 Nov;28(11):1062-1076. doi: 10.1038/s41422-018-0097-4. Epub 2018 Oct 8.
Ref 9 Meclofenamic acid promotes cisplatin-induced acute kidney injury by inhibiting fat mass and obesity-associated protein-mediated m(6)A abrogation in RNA. J Biol Chem. 2019 Nov 8;294(45):16908-16917. doi: 10.1074/jbc.RA119.011009. Epub 2019 Oct 2.
Ref 10 A review of contusugene ladenovec (Advexin) p53 therapy. Curr Opin Mol Ther. 2009 Feb;11(1):54-61.
Ref 11 The m(6)A RNA methyltransferase METTL3/METTL14 promotes leukemogenesis through the mdm2/p53 pathway in acute myeloid leukemia. J Cancer. 2022 Jan 4;13(3):1019-1030. doi: 10.7150/jca.60381. eCollection 2022.
Ref 12 Gene Signatures and Prognostic Values of m6A Regulators in Hepatocellular Carcinoma. Front Genet. 2020 Oct 2;11:540186. doi: 10.3389/fgene.2020.540186. eCollection 2020.
Ref 13 p53 m(6)A modulation sensitizes hepatocellular carcinoma to apatinib through apoptosis. Apoptosis. 2022 Jun;27(5-6):426-440. doi: 10.1007/s10495-022-01728-x. Epub 2022 May 3.
Ref 14 RNA Demethylase ALKBH5 Prevents Lung Cancer Progression by Regulating EMT and Stemness via Regulating p53. Front Oncol. 2022 Apr 22;12:858694. doi: 10.3389/fonc.2022.858694. eCollection 2022.
Ref 15 N(6)-methyladenosine mediates arsenite-induced human keratinocyte transformation by suppressing p53 activation. Environ Pollut. 2020 Apr;259:113908. doi: 10.1016/j.envpol.2019.113908. Epub 2020 Jan 7.